How Effective is Vaccination in Preventing Pneumococcal Disease?

Musher, Daniel M.

doi:10.1016/j.idc.2012.11.011

Cited by 14 publications

(16 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCV13 that is an updated version of PCV7, which improved antibody response with longer coverage against invasive pneumococcal disease in immunocompetent and immunocompromised persons. (58) PCV13 (Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) was approved by the FDA for adult based on immunogenicity studies. (59) PCV13 is a safe and effective strategy to prevent invasive pneumococcal disease and induces higher immune response as compared to PPSV23 in pneumococcal vaccine-naive adults.…”

Section: -Valent Pneumococcal Conjugate Vaccinementioning

confidence: 99%

Pneumococcal Vaccine and Patients with Pulmonary Diseases

Mirsaeidi

Ebrahimi

Allen

et al. 2014

The American Journal of Medicine

View full text Add to dashboard Cite

Chronic pulmonary diseases describe chronic diseases that affect the airways and lung parenchyma. Examples of common chronic pulmonary diseases include asthma, bronchiectasis, chronic obstructive lung disease, lung fibrosis, sarcoidosis, pulmonary hypertension and cor pulmonale. Pulmonary infection is considered a significant cause of mortality in patients with chronic pulmonary diseases. Streptococcus pneumoniae is the leading isolated bacteria from adult patients with community-acquired pneumonia, the most common pulmonary infection. Vaccination against S. pneumoniae can reduce the risk of mortality especially from more serious infections in both immunocompetent and immunocompromised patients. Patients with chronic pulmonary diseases who take steroids or immunomodulating therapy (e.g., methotrexate, anti-TNF inhibitors), having concurrent sickle cell disease or other hemoglobinopathies, primary immunodeficiency disorders, human immunodeficiency virus infection / acquired immunodeficiency syndrome (HIV/AIDS), nephrotic syndrome, and hematologic or solid malignancies should be vaccinated with both 13-valent pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine 23-valent (PPSV23).

show abstract

“…Two types of pneumococcal vaccines are available in the market, both based on the capsule polysaccharide: pneumococcal purified polysaccharide vaccine and conjugate vaccines, in which polysaccharides are conjugated to a protein carrier capable of recruiting CD4 + T-cells, increasing immunogenicity in young children [8]. The first type is mainly used in adults, covering 23 capsule serotypes (Pneumovax 23V) that represent about 80% of the most prevalent pneumococcal disease-causing ones in children and adults in the USA [9]. A pneumococcal conjugate vaccine covering 7 serotypes (PCV7) was initially licensed for exclusive use in children, and new vaccines with broader serotype coverage (10V and 13V) were later developed.…”

Section: Introductionmentioning

confidence: 99%

Identification of Potential New Protein Vaccine Candidates through Pan-Surfomic Analysis of Pneumococcal Clinical Isolates from Adults

et al. 2013

View full text Add to dashboard Cite

Purified polysaccharide and conjugate vaccines are widely used for preventing infections in adults and in children against the Gram-positive bacterium Streptococcus pneumoniae, a pathogen responsible for high morbidity and mortality rates, especially in developing countries. However, these polysaccharide-based vaccines have some important limitations, such as being serotype-dependent, being subjected to losing efficacy because of serotype replacement and high manufacturing complexity and cost. It is expected that protein-based vaccines will overcome these issues by conferring a broad coverage independent of serotype and lowering production costs. In this study, we have applied the “shaving” proteomic approach, consisting of the LC/MS/MS analysis of peptides generated by protease treatment of live cells, to a collection of 16 pneumococcal clinical isolates from adults, representing the most prevalent strains circulating in Spain during the last years. The set of unique proteins identified in all the isolates, called “pan-surfome”, consisted of 254 proteins, which included most of the protective protein antigens reported so far. In search of new candidates with vaccine potential, we identified 32 that were present in at least 50% of the clinical isolates analyzed. We selected four of them (Spr0012, Spr0328, Spr0561 and SP670_2141), whose protection capacity has not yet been tested, for assaying immunogenicity in human sera. All of them induced the production of IgM antibodies in infected patients, thus indicating that they could enter the pipeline for vaccine studies. The pan-surfomic approach shows its utility in the discovery of new proteins that can elicit protection against infectious microorganisms.

show abstract

“…31 Evidence for and against benefit of PPV23 in these settings has been extensively discussed elsewhere. 6,25,[32][33][34] There is also some controversy with regard to efficacy in IPD.…”

Section: Prevention Of Pneumococcal Infections -Vaccinationmentioning

confidence: 99%

“…34,[63][64][65] Additional limitations include: i) transient efficacy in the healthy elderly; ii) lack of efficacy in the frail elderly; iii) trivial impact on nasopharyngeal carriage of vaccine serotypes; iv) no effect on herd protection; and v) failure to induce mucosal immunity. Prior to a more detailed consideration of these emerging pneumococcal vaccines, candidate protein antigens, predominantly virulence factors, are updated in the following section, albeit briefly as many of these have been covered extensively in several recent reviews.…”

Section: Rationale For New Pneumococcal Vaccine Developmentmentioning

confidence: 99%

Review: Current and new generation pneumococcal vaccines

Feldman

2014

Journal of Infection

167

View full text Add to dashboard Cite

“…This increasing prevalence of invasive pneumococcal disease caused by the nonvaccine serotype 35B in the United States and the emergence of a new MDR clone due to capsular switching show, once again, the need for a pneumococcal vaccine that targets a conserved protein (26). Vaccine candidates include a protein that has a role in pathogenicity, such as pneumolysin, or one that is exposed on the bacterial surface and whose antibody would enhance ingestion and killing by white blood cells.…”

mentioning

confidence: 99%